Arvinas, Inc. (ARVN)
8.29
-0.02
(-0.24%)
USD |
NASDAQ |
Sep 18, 16:00
8.275
-0.02
(-0.18%)
After-Hours: 20:00
Arvinas Shares Outstanding (Quarterly) : 65.30M for June 30, 2026
Shares Outstanding (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shares Outstanding (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 65.30M |
| March 31, 2026 | 64.50M |
| December 31, 2025 | 63.50M |
| September 30, 2025 | 70.80M |
| June 30, 2025 | 73.20M |
| March 31, 2025 | 73.00M |
| December 31, 2024 | 68.80M |
| September 30, 2024 | 68.70M |
| June 30, 2024 | 68.60M |
| March 31, 2024 | 68.30M |
| December 31, 2023 | 68.00M |
| September 30, 2023 | 55.00M |
| June 30, 2023 | 53.40M |
| March 31, 2023 | 53.40M |
| December 31, 2022 | 53.20M |
| September 30, 2022 | 53.20M |
| June 30, 2022 | 53.20M |
| March 31, 2022 | 53.10M |
| December 31, 2021 | 53.00M |
| Date | Value |
|---|---|
| September 30, 2021 | 52.77M |
| June 30, 2021 | 48.99M |
| March 31, 2021 | 48.79M |
| December 31, 2020 | 48.46M |
| September 30, 2020 | 40.10M |
| June 30, 2020 | 38.83M |
| March 31, 2020 | 38.67M |
| December 31, 2019 | 38.46M |
| September 30, 2019 | 33.08M |
| June 30, 2019 | 31.52M |
| March 31, 2019 | 31.37M |
| December 31, 2018 | 31.24M |
| September 30, 2018 | 32.35M |
| June 30, 2018 | 32.16M |
| March 31, 2018 | 32.16M |
| December 31, 2017 | 32.16M |
| September 30, 2017 | 32.16M |
| June 30, 2017 | 32.16M |
| March 31, 2017 | 32.16M |
Shares Outstanding Definition
The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.
Shares Outstanding (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shares Outstanding (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | 13.79M |
| CNBX Pharmaceuticals, Inc. | 1.476B |
| GB Sciences, Inc. | -- |
| Fulcrum Therapeutics, Inc. | 76.29M |
| Definium Therapeutics, Inc. | 134.37M |